Home > Press > Starpharma Holdings Limited (ASX:SPL) Announce Key VivaGel(R) Patent Approved in Japan
 |
Abstract:
Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) today announced that one of its key patents relating to the use of dendrimers to protect against sexually transmitted infections has been approved in Japan.
Starpharma Holdings Limited (ASX:SPL) Announce Key VivaGel(R) Patent Approved in Japan
Melbourne, Australia | Posted on October 29th, 2008This approval means that VivaGel(R) and the VivaGel(R) coated condom are now covered by granted patents in all major markets including Europe, the US and Japan.
Last month Starpharma announced a full licence agreement with SSL International plc (LON:SSL) in relation to the VivaGel(R) coated condom, with estimated receipts in excess of A$100m comprising royalties, milestone payments and development support. In addition Starpharma is continuing to develop VivaGel(R) as a stand-alone product for use by women to protect themselves from HIV and HSV-2 (genital herpes). The development for these two indications has significant NIH support.
####
About Starpharma Holdings Limited
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc in Michigan, USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.
The Company's lead pharmaceutical development product is VivaGel(R) (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes.
For more information, please click here
Contacts:
Dr Jackie Fairley
Chief Executive Officer
TEL: +61-3-8532-2704
Copyright © Starpharma Holdings Limited
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Bookmark:
| Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||